Halma plc ('Halma' or the
'Group')
Acquisition
Halma, the global group of life-saving
technology companies focused on growing a safer, cleaner, healthier
future for everyone, every day, today announces that it has
acquired Lamidey Noury Medical.
Founded in 1947 and headquartered close to
Paris, Lamidey Noury manufactures advanced electrosurgical and
associated energy devices which are used in minimally invasive
urology, gynaecology, and general surgery. Its products are sold to
healthcare providers in over 60 countries.
The cash consideration for Lamidey Noury is €50m
(approximately £42m), on a cash- and debt-free basis, to be funded
from Halma's existing facilities.
Lamidey Noury's unaudited revenue for the 12
months to October 2024 was €13.6m (approximately £11.4m), with an
EBIT margin above the upper end of Halma's target range of 19-23%.
Lamidey Noury will be a standalone company within Halma's
Healthcare Sector, led by its current management
team.
Marc Ronchetti, Group Chief Executive of Halma,
commented:
"Lamidey Noury is an exciting acquisition which
will bring new minimally invasive surgical product capabilities to
our Healthcare Sector. Its advanced products improve patient
outcomes and the efficiency of healthcare providers in treating the
increasing incidence of urological and gynaecological disease. It
is adjacent to our existing presence in diagnosis and biopsy
devices for these diseases through Rovers Medical Devices and IZI
Medical. We are delighted to welcome Lamidey Noury to Halma and
look forward to supporting its development as it continues to scale
its business globally."
Guillaume Noury, President of Lamidey Noury
said:
"Joining Halma is an exciting opportunity for
us. Leveraging Halma's expertise, resources, and global reach will
accelerate our growth and innovation. We are confident in our ability to continue
delivering high-quality surgical tools to our customers worldwide,
while providing new opportunities for our employees and
stakeholders. Together, we will continue improving patient outcomes
and driving excellence in
healthcare."
For further information, please
contact:
Halma
plc
Marc Ronchetti, Group Chief Executive
+44
(0)1494 721111
Steve Gunning, Group Chief Financial
Officer
Charles King, Head of Investor Relations
+44 (0) 7776
685948
Clayton Hirst, Director of Corporate Affairs
+44 (0) 7384 796 013
MHP
Oliver Hughes / Rachel Farrington / Ollie Hoare
+44 (0)20 3128 8100 / +44 (0)7817 458 804 / halma@mhpgroup.com
A copy of this announcement, together with other
information about Halma, is available at www.halma.com.
About
Halma
Halma is a global group of life-saving
technology companies, focused on growing a safer, cleaner,
healthier future for everyone, every day. Its purpose defines the
three broad markets it operates in:
· Health - Meeting
the increasing demand for better healthcare as chronic illness
rises, driven by growing and ageing populations and lifestyle
changes.
· Environment -
Addressing the impacts of climate change, pollution and waste,
protecting life-critical resources and supporting scientific
research.
· Safety -
Protecting the safety of people and assets as populations grow and
the demand on infrastructure increases.
It employs over 8,000 people in more than 20
countries, with major operations in the UK, Mainland Europe, the USA and Asia
Pacific. Halma is listed on the London Stock Exchange (LON: HLMA)
and is a constituent of the FTSE 100 index.
Halma has been named as one
of Britain's Most
Admired Companies for the past six years.
For more information www.halma.com
ENDS